

TyRx PHARMA, INC.

FOR IMMEDIATE RELEASE

Contact:

Bill Edelman
CEO, TyRx Pharma, Inc.
Office 732-246-8676
Direct: 732-964-1101
Cell: 617-759-5451
william@tyrxpharma.com

TyRx Announces FDA 510(k) Filing for New Surgical Mesh

Monmouth Junction, NJ (October 17, 2005) – TyRx Pharma, Inc. announced today the filing of a 510(k) application with the FDA for their new bioresorbable polymer coated surgical mesh product on Friday, October 7th.

The TyRx bioresorbable polymer surgical mesh is indicated for the repair of hernias and other abdominal fascial or muscular deficiencies requiring the addition of a reinforcing or bridging material to obtain the desired surgical result.

“We are extremely excited to have reached this value-creating milestone with our new surgical mesh,” said Bill Edelman, CEO of TyRx Pharma. “We feel that the features of this product will help to alleviate some of the problems associated with mesh implantation for the treatment and repair of hernia. The unique properties associated with this product give the surgical mesh good handling characteristics that facilitate precise placement during the surgical repair and leaves less implant material following the resorption of the bioresorbable polymer coating. We believe that less implant material will help to facilitate patient comfort during the post-operative period and beyond.”

TyRx expects to launch this new surgical mesh in Q1-06. This is the first in a series of combination medical products that TyRx expects to market next year.

This notice follows TyRx’s May 9, 2005 announcement that the company named William McJames and Dr. Mason Diamond to the TyRx management team.

In January 2005, TyRx received an equity investment from **Boston Scientific Corporation**. Since 2002, Boston Scientific and TyRx have been co-developing novel drug eluting coatings for cardiovascular stents under a licensing agreement. TyRx is focused on developing a family of proprietary bioresorbable drug-eluting polymers for use in combination medical devices and specialty pharmaceuticals. Terms of the agreement were not disclosed. The law firm of Brown Rudnick Berlack Israels LLP represented TyRx Pharma in the financing round.

About TyRx Pharma, Inc.

TyRx was organized in 1998 to advance its core technology – a novel class of tyrosine-based biodegradable polymers, referred to as polyarylates. Using combinatorial chemistry, TyRx has created libraries of related polymers with systematically varied chemical structures and predictable physical properties. Using a proprietary polymerization process, TyRx has synthesized and characterized over 100 tyrosine-based polymers that allow TyRx to quickly create custom polymers to meet precise product specifications. TyRx is deploying its coating and delivery technologies across a broad range of medical devices. Combination products are expected to be the highest growth segment of the medical device industry and TyRx is positioned to be an innovative applications leader in the space.

TyRx Pharma, Inc. designs, develops, and commercializes innovative combination medical devices and drug delivery products using patent protected tyrosine-derived polyarylate polymers. For more information, please visit: www.tyrxpharma.com.

###